EPIGEN INC /DE
SC 13D, 1999-07-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: EPIGEN INC /DE, SC 13D, 1999-07-14
Next: CENTENNIAL CELLULAR CORP, 10-Q/A, 1999-07-14



                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13D
                                 (Rule 13d-101)

            INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
           TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
                                  RULE 13d-2(a)

                                (Amendment No. 5)


                                  Epigen, Inc.
                                (Name of Issuer)

                                  Common Stock
                         (Title of Class of Securities)

                                   294259 10 G
                                 (CUSIP Number)

       Colin K. Harley, Harley & Deickler, P.O. Box 264 Woodbury, CT 06798
                                  203-263-2469
                  (Name, Address and Telephone Number of Person
                Authorized to Receive Notices and Communications)


             (Date of Event Which Requires Filing of This Statement)

          If the filing person has previously  filed a statement on Schedule 13G
to report the  acquisition  that is subject to this  Schedule 13D, and is filing
this  schedule  because  of Rule  13d-1(e),  13d-1(f)  or  13d-1(g),  check  the
following box [_].

          Note.  Schedules filed in paper format shall include a signed original
          and five copies of the  schedule,  including  all  exhibits.  See Rule
          13d-7(b) for the other parties to whom copies are to be sent.

                               (Page 1 of 2 Pages)


<PAGE>


CUSIP NO. 294259 10 G                13D                       Page 2 of 2 Pages


 1. NAMES OF REPORTING PERSONS                -                 Donald C. Fresne
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*                     (a)[_]
                                                                          (b)[X]

 3. SEC USE ONLY

 4. SOURCE OF FUNDS* - Conversion of debt owed by Issuer to Reporting Person

 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEM 2(D) OR 2(E)                                                     [_]

 6. CITIZENSHIP OR PLACE OF ORGANIZATION  -  UNITED STATES

NUMBER OF                   7. SOLE VOTING POWER  -  2,949,873
SHARES
BENEFICIALLY                8. SHARED VOTING POWER  -  0
OWNED BY
EACH                        9. SOLE DISPOSITIVE POWER  -  2,949,873
REPORTING
PERSON WITH                10. SHARED DISPOSITIVE POWER  -  0

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON - 2,949,873

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*   [_]

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) - 51.88%

14. TYPE OF REPORTING PERSON*  -  IN

                                    SIGNATURE

          After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information  set forth in this statement is true,  complete and
correct.

                                                 7/12/99
                                         ----------------------
                                                 (Date)

                                         /s/Donald C. Fresne
                                         ----------------------
                                               (Signature)

                                         ----------------------
                                         Donald C. Fresne, CEO
                                         President, Chairman



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission